Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Arcus Biosciences (RCUS) EBT: 2017-2024

Historic EBT for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to -$282.0 million.

  • Arcus Biosciences' EBT fell 46.74% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$432.0 million, marking a year-over-year decrease of 60.59%. This contributed to the annual value of -$282.0 million for FY2024, which is 6.31% up from last year.
  • Per Arcus Biosciences' latest filing, its EBT stood at -$282.0 million for FY2024, which was up 6.31% from -$301.0 million recorded in FY2023.
  • Arcus Biosciences' EBT's 5-year high stood at $55.0 million during FY2021, with a 5-year trough of -$301.0 million in FY2023.
  • Moreover, its 3-year median value for EBT was -$282.0 million (2024), whereas its average is -$283.0 million.
  • Per our database at Business Quant, Arcus Biosciences' EBT skyrocketed by 144.72% in 2021 and then tumbled by 583.64% in 2022.
  • Arcus Biosciences' EBT (Yearly) stood at -$123.0 million in 2020, then skyrocketed by 144.72% to $55.0 million in 2021, then tumbled by 583.64% to -$266.0 million in 2022, then fell by 13.16% to -$301.0 million in 2023, then rose by 6.31% to -$282.0 million in 2024.